Published in final edited form as:

Sci Transl Med. 2012 May 23; 4(135): 135ra67. doi:10.1126/scitranslmed.3003815.

Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis

Rinat Sergeev^{1,2,*}, Caroline Colijn³, Megan Murray^{1,4}, and Ted Cohen^{1,4}

¹Department of Medicine, Brigham and Women's Hospital, 641 Huntington Ave, 02115, Boston, MA, USA

²Department of Microelectronics, Ioffe Institute, 26 Polytekhnicheskaya, St Petersburg 194021, Russia

³Department of Mathematics, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom

⁴Department of Epidemiology, Harvard School of Public Health, 641 Huntington Ave, 02115, Boston, MA, USA

Abstract

The emergence of highly drug-resistant tuberculosis (TB) and interactions between TB and HIV epidemics pose serious challenges for TB control. Previous researchers have presented several hypotheses for why HIV-coinfected TB patients may suffer an increased risk of drug-resistant TB compared to other TB patients. Although some studies have found a positive association between an individual's HIV status and her subsequent risk of multidrug-resistant TB (MDRTB), the observed individual-level relationship between HIV and drug-resistant TB varies substantially among settings. Here, we develop a modeling framework to explore the effect of HIV on the dynamics of drug-resistant TB. The model captures the acquisition of resistance to important classes of TB drugs, imposes fitness costs associated with resistance-conferring mutations, and allows for subsequent restoration of fitness due to compensatory mutations. Despite uncertainty in several key parameters, we demonstrate epidemic behavior that is robust over a range of assumptions. Whereas HIV facilitates the emergence of MDRTB within a community over several decades, HIV-seropositive individuals presenting with TB may, counter-intuitively, be at lower risk of drug resistant TB at early stages of the co-epidemic. This situation arises because many individuals with incident HIV infection will already harbor latent *Mycobacterium Tuberculosis* infection acquired at an earlier time when drug-resistance was less prevalent. We find that the rise of HIV can increase the prevalence of MDRTB within populations even as it lowers the average fitness of circulating MDRTB strains compared to similar populations unaffected by HIV. Preferential social mixing among individuals with similar HIV-status and lower average CD4

*Corresponding author. Tel.: +1 617 780 9771; fax: +1 617 432 2565.

While HIV co-epidemics are likely to increase the overall burden of drug-resistant TB, our model demonstrates that, paradoxically, HIV-coinfected TB patients may be less likely to be affected by drug-resistant TB than others in their communities as resistance first emerges.

Supplementary Materials

Figure S1. Fitness costs for the strains

Figure S2. Assumed patterns for case-finding, treatment success and failure chance

Figure S3. Uncertainty analysis

Figure S4. Partial rank correlation coefficients

Figure S5. Simulation of pessimistic scenario for MDRTB control

Figure S6. Cumulative effect of the mechanisms promoting HIV-MDRTB association

Table S1. Model parameters

Competing interests: The authors declare that they have no competing interests.

counts among HIV-seropositive individuals further increase the expected burden of MDRTB. This model suggests that the individual-level association between HIV and drug-resistant forms of TB is dynamic and therefore cross-sectional studies that do not report a positive individual-level association will not provide assurance that HIV does not exacerbate the burden of resistant TB in the community.

Keywords

Epidemiology; Mycobacterium; Mathematical model; Antibiotic resistance; Fitness; Evolution

Introduction

There were 8.8 million new cases of tuberculosis (TB) in 2010, with nearly 1.5 million TB-associated deaths despite the availability of antibiotic therapy [1]. Two factors that contribute to the continued morbidity and mortality of TB are its association with the human immunodeficiency virus (HIV) epidemic [2,3] and the appearance of drug-resistant TB (DRTB) [4] [5]. On one hand, HIV infection increases the probability of developing active TB disease after infection as a result of immunosuppression [6] and HIV epidemics have led to dramatic rises in the incidence of TB [7–9]. On the other hand, drug-resistant *Mycobacterium Tuberculosis* (*M. Tb*), which cannot be treated by standard therapies, not only poses problems for the treatment of affected individuals, but also for the control of TB in populations [10].

HIV and DRTB constitute two distinct obstacles for TB control; however, when combined their synergistic effect is dramatic: in an outbreak of extensively drug resistant TB (XDRTB) occurring among HIV-infected individuals in KwaZulu-Natal, South Africa, 52 of 53 patients affected died, with a median time of death after detection of 16 days [11]. The collision of these two epidemics has raised international concern about epidemics of essentially untreatable forms of tuberculosis [12].

Simple inference alone cannot explain the effect of HIV on *M. Tb* drug resistance, and whether HIV is selectively beneficial for the development of DRTB is still not clear [13]. On a community level, HIV is expected to increase both the prevalence of DRTB and the total *M. Tb* burden in the population [14], despite lower levels [15,16] and shorter duration [17] of infectiousness of HIV-coinfected individuals. In 2002, Dye presented five hypotheses that might explain an association between HIV infection and an increased risk of DRTB [18]. He suggested that 1) immunocompromised hosts may be at more risk of disease from low-fitness drug-resistant *M. Tb* strains; 2) newly circulating DRTB will appear earlier among the HIV infected than the uninfected because HIV patients are at the highest risk for progression after infection; 3) HIV and DRTB may be jointly distributed because patients may have shared risk factors for the two infections, such as injection drug use, incarceration, and hospitalization; 4) HIV-infected TB patients may have larger mycobacterial burdens and therefore be more likely to harbor DR mutations; and 5) HIV-infected patients may have reduced drug absorption or more limited therapeutic options and thus have a higher risk of sub-optimal TB treatment.

There are a limited number of studies that have tested the individual-level association of HIV infection and DRTB emergence; an unbiased estimate can be obtained only when HIV and TB drug resistance are tested among all TB patients or in settings where population-representative DRTB surveys with obligatory testing on HIV have been employed. The World Health Organization has reported [5] (Figure 1a) a positive association between HIV infection and multidrug resistant TB (MDRTB) in some European and North American

countries, consistent with Dye's hypotheses. However, a recent literature review of earlier surveys from Sub-Saharan African countries [19] (Figure 1b) does not support this association. Instead, it suggests that in the countries where HIV was rapidly emerging in areas with relatively low levels of anti-tuberculosis drug resistance, the nature of the individual-level association may be different. Conversely, a new study from Swaziland [20] performed in 2009–2010 shows a strong individual-level association between MDRTB and HIV.

Mathematical models have been increasingly used to understand the behavior of epidemics. In the case of the interacting epidemics of HIV and TB, which occur in settings where data are limited, models can play a key role in explaining complex patterns. In this paper, we describe a model that is designed to explore the dynamic individual-level relationship between HIV and drug-resistant forms of TB as epidemics progress in communities where the burdens of both HIV and TB are high. The model builds on our understanding of how drug-resistant *M. Tb* is selected within hosts during ineffective treatment and is subsequently spread within the population. We address diversity both in terms of drug resistance profiles and fitness costs of different *M. Tb* strains and in terms of the HIV status of the host. Our results have implications for the design and interpretation of surveillance studies and suggest that the cross-sectional studies of the individual-level association between MDRTB and HIV may not be a useful marker of the propensity of HIV to increase the burden drug-resistant TB.

Results

Model

We developed a differential equation model of the TB-HIV co-epidemics that classified hosts by infection/disease status (Figure 2a) and mycobacteria by level of drug-resistance and reproductive fitness (Figure 2b)—the ability of an infecting mycobacterium to cause TB disease within that host and be successfully transmitted to others. A simplified overview of the model is presented in Materials and Methods below; the complete model description with the full set of equations and parameters (Table S1) as well as details of the multivariable sensitivity analysis [21] are provided in the Supplementary Materials.

We chose Swaziland as a motivating example of a setting with a severe HIV epidemic and growing levels of DRTB, and we fit the model to trends in estimated TB incidence and HIV prevalence (Figure 3a), assuming that case-finding and treatment success followed reported by WHO [22] patterns (inset of the figure). The model generated reasonable fits to the current estimated frequencies [20] of MDRTB among new (7.7%) and retreatment (34%) cases. The model also reproduced (without fitting) the fraction of incident TB cases that are coinfecting with HIV: (78% from the model compared with 82% from Swaziland [20]).

We used a prevalence ratio (*PR*) as the measure of association between DRTB and HIV. The *PR* was calculated as the ratio of the proportion of TB cases that are were drug resistant among HIV-seropositive individuals to the proportion of TB cases that are were drug resistant among HIV-seronegative individuals. Accordingly, when a $PR > 1$ there is indicated a positive association between HIV and DRTB among individuals with TB, and when a $PR < 1$ there is indicated a negative association. In order to assess the effect of HIV on the community burden of DRTB, we also performed comparative simulations under the counterfactual scenario where HIV did not enter the population.

Impact of HIV on the total incidence of TB and DRTB

Figure 3b displays the simulated trends of TB incidence in two (otherwise identical) populations: one with a co-occurring HIV epidemic (solid lines) and the other free of HIV

(dotted lines). As expected, the introduction of HIV caused a reversal of secular declines in overall TB incidence [23] and an increase of the absolute incidence of drug-resistant forms of TB (compare solid and dotted curves for DR, MDR and XDR). The return to sustained reductions in TB incidence overall, and drug resistant forms of TB in particular, that occurred after the peak of HIV incidence were dependent upon continued high rates of TB case finding and treatment success and assumptions of lower reproductive fitness of drug-resistant strains compared with drug-sensitive strains. In the Supplement (Figure S5) we offer additional results that show that the central findings presented here are unchanged when TB and DRTB rise over the course of the simulations, which may realistically occur if treatment programs are not sustained and extended to cover drug resistant disease, or if fitness costs associated with resistance can be completely compensated by the mycobacteria.

Association between DRTB and HIV

Figure 4 shows that the individual-level association between HIV and DRTB (*PR*, right panels) may change dramatically over time. During the period of early emergence and exponential rise of HIV, we observed that the risk of resistance among TB patients was *lower* among those with HIV infection than it was among those without HIV infection. The model projected this early negative association between HIV and DRTB for all classes of drug resistance, but was most dramatic for the most common (and least severe) forms. As the HIV epidemic matured, this pattern was reversed and we saw a positive association between HIV and DRTB emerge; moreover, also in contrast to the early period, during this later stage the positive association between HIV and DRTB increased for more extreme forms of resistance. Consistent with the review cited above [19], we found that the association between DRTB and HIV was substantially more pronounced for DRTB among cases without prior treatment than among cases with previous treatment (Figure 4c, right panel). The relative contributions of transmission of resistant strains and acquisition of resistance during treatment (Figure 4c, left panel) are expected to change during the epidemic, with acquired resistance dominating early and transmitted resistance increasing in importance over time. This transition is expedited by a substantial improvement in quality of TB treatment programs focused on effective delivery of first-line drug regimens between 2000–2010 (see inset of Figure 3a), which reduced the relative probability of resistance acquired during treatment.

Effect of HIV on average strain fitness

While the average relative reproductive fitness of resistant strains increased over time as the most reproductively fit strains preferentially cause disease and are transmitted [24], the presence of HIV within the population allowed for strains of lower reproductive fitness to succeed and thus the average fitness of resistant strains was reduced (compare solid to dotted lines in Figure 5a). When we compared HIV-seronegative hosts in populations affected by HIV with individuals in populations free of HIV, we found similar average fitness of resistant strains. This suggests that the reduction of DRTB fitness observed at the community level in the presence of HIV was restricted to the immunocompromised hosts. Figure 5b shows that the strains of lowest fitness (solid lines) were predominately restricted to immunocompromised individuals (reflected by a high positive value of individual level association, $PR > 1$), while strains of higher fitness (dashed lines) also spread into the immunocompetent population.

Sensitivity of the results to uncertain parameter values

To examine the influence of model parameters on behavior, we conducted a multivariable sensitivity analysis by Latin Hypercube Sampling (LHS) [21] (Figure 6, see also Supplementary Materials for details and sensitivity/uncertainty analysis results). We found that while the HIV (panel b) and TB (panel c) epidemic trajectories were modified by

changes in parameter values, the key qualitative finding in the trend MDRTB prevalence ratio was quite robust. In particular the *PR* trajectories on Figure 6a fell within a narrow range and demonstrate a stable monotonic growth of the individual-level association between MDRTB and HIV that crosses from negative to positive over time. In the Supplementary Materials (see Figure S3a), we showed that variation over assumed ranges of each parameter resulted in less than 10% change in the value of the time-derivative of *PR*, further demonstrating that this trend is not sensitive to uncertainty in our input parameter values.

In the examples below, we examined the impact of several parameters related to Dye's proposed mechanisms [18] on the association between HIV and DRTB and the projected trajectory of DRTB within communities (Figure 7).

1) Differences in the vulnerability of immunocompromised individuals to be infected by low-fitness strains—While there is some support for the claim that specific strains of relatively low-fitness, highly-drug resistant TB appear to be able to cause disease only among those with impaired immune systems [25,26], the actual value of this “fitness threshold” is not known. Furthermore, since the distribution of severity of immunosuppression changes with HIV epidemic phase and availability of antiretroviral therapy [27], we explored the effect of altering the fitness threshold for HIV-seropositives on the proportion of all TB that is MDR (Figure 7a). As we increased the fitness threshold for HIV-coinfected patients from the original value (increasing this threshold means that less fit strains were not capable of infecting immunocompromised hosts), the expected frequency of MDRTB in this vulnerable subpopulation (left panel) as well as the association between MDRTB and HIV (right panel) was reduced. These results demonstrated that the relative fitness threshold of immunocompromised individuals has an influence on the individual-level association between HIV and DRTB and anticipated burden of DRTB.

2) Mixing patterns—For the baseline results, we assumed respiratory contacts (i.e. contacts sufficient for transmission of *M. Tb*) were equally likely to occur among any members of the population. This assumption would be violated if there is preferential association between individuals of similar HIV status due to social preference or because individuals with HIV infection are more likely to contact each other within hospitals or other institutional settings. Figure 7b showed that as the likelihood of having respiratory contact with those of similar HIV status rises, there were short-term increases in the individual-level association for MDR among HIV infected TB patients (right panel), but this effect waned over time.

3) Differences in case finding—The natural history and clinical presentation of TB disease differs between patients with and without HIV coinfection and also as a function of severity of HIV-associated immunosuppression [28]. In some settings, individuals with HIV may be more likely than those without HIV to be diagnosed rapidly after onset of TB infectiousness [29] while in other settings this might not be true [16]. To examine the sensitivity of the model to possible differences in access to diagnosis, we varied the rate with which HIV-seropositive individuals with active TB are detected and placed on treatment. Figure 7c showed that differences in TB case-finding by HIV status of hosts can substantially modify the expected individual-level association between HIV and DRTB. Higher rates of case finding among those with HIV resulted in greater overall usage of drugs, higher proportions of TB being MDR (left panel), and a more rapid appearance of a positive individual-level association for MDR among HIV-infected TB patients (right panel).

In addition to considering each of these proposed mechanisms alone, we found that when these factors were present in combination there was a more pronounced positive association between HIV and MDRTB throughout the epidemic. (Figure S6).

Discussion

Our model expands existing dynamic models of TB and DRTB to consider the emergence of drug resistant strains of *M. Tb* in the presence of HIV. While previous models touch on related questions of emergence of DRTB, including amplification [30], coexistence [31–33], and interactions with HIV [34–38], we are not aware of other models that have attempted to represent the process of acquisition of multiple drug resistance in *M. Tb*, the effects of resistance-associated fitness deficits [24,39,40], and compensation for these reproductive costs [41,42]. This model allowed us to investigate whether the potential HIV-associated host effects summarized by Dye [18] which reduce immune integrity, accelerate the natural history of TB, and offer opportunities for strain evolution, can essentially serve as “stepping stones” [43] for the appearance and spread of highly drug resistant forms of TB.

We found that the rise of HIV within populations was likely to result in an increased incidence of DRTB, as HIV causes an overall increase in the incidence of all forms of TB. However, we also found that the *individual-level* association between HIV and DRTB may not be a useful proxy measure to indicate whether HIV is acting to facilitate the emergence of drug resistant TB on the population level. In particular, we found that TB patients with HIV-coinfection may actually be *less* likely to have MDRTB disease than other TB patients without immunocompromise as HIV is first emerging within the population. While this counterintuitive relationship (i.e. HIV increasing the level of DRTB at the population-level while being inversely associated with DRTB at the individual-level) is only temporary, it reveals the complex interaction between these epidemics with different time-scales (see Hypothesis 2 below).

We return to Dye’s initial hypotheses [18] to assess what additional insight is offered by this model:

Dye’s Hypothesis 1: *Immunocompromised hosts may be at more risk of disease from low-fitness drug-resistant M. Tb strains.* Figure 7a demonstrated that enhanced sensitivity of immunocompromised hosts to low-fitness *M. Tb* strains does act to increase the association between DRTB and HIV. However, we found that even if we assume a similar fitness threshold for HIV infected and HIV-uninfected hosts, we saw an increasing individual-level relationship between HIV and MDRTB and an increase in DRTB strains overall in the presence of HIV. Furthermore, the impact of a lower fitness threshold was more important for strains with higher levels of resistance (e.g. XDR) and thus enhanced vulnerability to low-fitness TB strains provided by HIV may indeed serve as an important “stepping stone” on the way to emergence of highly drug resistant TB strains that are able to recover fitness costs and eventually spread among immunocompetent persons.

Dye’s Hypothesis 2: *Newly circulating DRTB will appear earlier among the HIV infected than the uninfected since HIV patients are at the highest risk for progression after infection.* While newly circulating strains of DRTB may first appear among those with HIV co-infection, the individual-level association between HIV and DRTB may actually be negative. When HIV first invades a population, many (if not most) of the individuals with incident HIV infections will harbor latent *M. Tb* infections acquired many years in the past when there was a very low prevalence of DRTB. As a result, these individuals with pre-existing latent *M. Tb* infections and incident HIV will be at high risk of progression to *drug-sensitive* TB. In contrast, HIV-seronegative individuals with incident TB, despite having a

similar risk of harboring a latent infection with a drug-sensitive strain as those with HIV, are more likely to have TB disease that is due to a recent re-infection event than to reactivation of a previous infection. Our simulation for Swaziland showed that in early stage of HIV invasion, up to 68% of TB cases among HIV-negatives were the result of recent infection or reinfection compared with only 24% among HIV-positives. The early inverse association observed between HIV and MDRTB ($PR < 1$) among new TB patients also supported this conclusion (right panel of Figure 4c).

Dye's Hypothesis 3: *HIV and DR TB may be jointly distributed because patients may have shared risk factors for the two infections, such as injection drug use, incarceration, and hospitalization.* Preferential mixing of highly susceptible HIV-seropositive individuals promoted the transmission of low-fitness drug resistant strains and boost the frequency of MDR (left panel of Figure 7b). These mixing patterns may act to increase the effective force of TB infection among HIV-seropositives, thus accelerating the transmission of all TB, including highly drug resistant strains, especially within nosocomial settings [11,44,45]. However, the longer-term effect of these mixing patterns on the total burden of MDR strains may be less pronounced, and are greatly diminished if drug-resistant forms of disease begin to spread outside settings where highly vulnerable individuals are concentrated. While it is possible that the concentration of immunocompromised individuals within nosocomial or prison settings can allow for the emergence of novel, low-fitness highly-drug resistant strains of TB that can subsequently compensate for initial fitness costs and be transmitted among immunocompetent hosts, this model does not allow us to gain quantitative insight into the likelihood of such an event.

Dye's Hypotheses 4 and 5: *HIV infected TB patients may have larger mycobacterial burdens and therefore be more likely to harbor DR mutations, and HIV infected patients may have reduced drug absorption or more limited therapeutic options and thus have a higher risk of sub-optimal TB treatment.* The differences in clinical presentation of TB disease among those with and without HIV-coinfection affect the probabilities of timely disease detection, of treatment after disease, and of outcome after treatment. While the probability of acquiring resistance, according to Dye's arguments, may be higher for HIV-coinfected TB patients on treatment, the relative probability that an HIV-coinfected individual with TB disease is actually diagnosed with TB and initiated into treatment differs between settings. In our model, inadequate case-finding among HIV co-infected TB patients (Figure 7c) resulted in less treatment applied, lower levels of drug resistance, and a reduction of the individual-level association between HIV and DRTB.

Our model results are broadly consistent with the small number of studies of the individual-level association between HIV and DRTB: there is no clear association in early studies within Sub-Saharan Africa [46–52] as HIV and DRTB were first appearing, whereas in areas with longer, more severe DRTB epidemics (such as Eastern Europe [53–55]), there is a more clear positive association between HIV and DRTB. Our results also support previous observations [19] of a greater positive individual-level association between MDR and HIV for transmitted than for acquired resistance (Figure 4c). We believe that this model provides a mechanistic explanation for why the individual-level association between HIV and MDRTB may be negative even as HIV is causing higher absolute levels of DRTB than would have otherwise been expected.

As with all models, we made important simplifying assumptions. We greatly reduced the complexities of the natural histories of both diseases considered in the model. Our model was not age-structured, described only the adult population, and assumed that the level of host immunosuppression was the same for all HIV-positive hosts and is constant over time. We evaluated the sensitivity of the model to some of these simplifications and found, for

example, that changes in the level of the fitness threshold (Figure 7a) which may serve as a marker of average level of HIV-related immunosuppression (which will change with access to antiretroviral therapy), did not affect the central qualitative results that we reported. We also assumed that the probability of acquisition and fitness costs of resistance and compensation were similar across classes of drugs. While TB drug resistance is generally mediated through chromosomal mutations (though some recent data implicate other mechanisms such as efflux pump activation) [56,57], the rates of acquisition of DR actually vary by drug, and each resistance-associated genotype may have a unique profile in terms of fitness effects and the probability of compensation [58]. These parameters are also likely to differ by mycobacterial lineage [59–61]. We also have not accounted for stochastic effects and reserve our main comments to the qualitative behaviors of relatively well-populated model classes (e.g. MDR rather than XDR and more resistant strains). We have also assumed in our base case scenario that tuberculosis detection and treatment success will continue at high levels in the future and that drug resistant forms of disease will also be effectively detected and treated such that there will be steady and sustained declines in all tuberculosis and more rapid declines in DRTB over the next several decades. This is an optimistic assumption and these stable improvements are dependent on many uncertain factors (including that drug resistant strains continue to harbor some fitness costs). Accordingly, these simulations are not meant to serve as predictions of what will happen in the future and in many areas with poor TB infrastructure we would expect that control of DRTB epidemics may not be as successful. However, we showed in the Supplementary Materials (Figure S5) that the central findings we reported here about how HIV and the drug resistant TB epidemic interact are robust to the projected long-term trends in these epidemics or assumptions about how effective tuberculosis case-finding and treatment was over the past several decades.

This model offers new insight into how the spread of HIV in areas with endemic TB can affect the emergence of DRTB. In particular, this model helps to better explain why HIV may be associated with increased individual-level risk of DRTB in some settings but not in others, and how these individual-level relationships can change as these epidemics progress together. Accordingly, longitudinal studies that can evaluate the dynamic nature of this individual-level association will be useful, and single cross-sectional studies should be interpreted with caution. Serial surveys in areas where surveillance systems are less robust, such as Sub-Saharan Africa, are likely to be especially informative.

Materials and Methods

We used a differential equation model of TB-HIV co-epidemics that classified hosts by infection/disease status (Figure 2a) and mycobacteria by level of drug-resistance and reproductive fitness (Figure 2b), i.e. the ability of an infecting mycobacterium to cause TB disease within that host and be successfully transmitted to others. In the main text, we presented a simplified overview of the model; the complete model description with the full set of equations and parameters (Table S1) is provided in the Supplementary Materials.

TB transmission component of model

We categorized hosts according to their status of TB into three broad classes: *S* – Susceptible; *L* – Latently infected; and *I* – Infectious (Figure 2a). Individuals entered the model as susceptible to TB infection (e.g. birth or immigration) and exited this compartment upon infection or death. A fraction of those infected with *M. Tb* developed TB rapidly (fast progressors), whereas the remainder contained the infection and entered a period of asymptomatic and non-infectious latency. The majority (~90%) of immunocompetent (i.e. not HIV-infected) latently infected individuals did not reactivate during their lifetimes [62]. Latently infected individuals could be reinfected upon subsequent exposure to *M. Tb* and

these people experienced an increased risk of developing fast TB, although this risk was less than would occur after a first infection [63,64]. Individuals with active TB suffered an increased mortality rate, but could control the infection and survive if they either received curative treatment or experience “self-cure” [65]. TB transmission could occur as a result of contact between an individual with active disease and an individual who was either Susceptible or Latently infected.

Heterogeneity among hosts: incorporating HIV co-infection

In addition to TB infection/disease status, we also distinguished individuals by HIV infection status, denoting those infected with HIV by the superscript ‘+’ (Figure 2a). We simplified the natural history of HIV infection in this model by incorporating HIV as a binary variable (infected/not infected classes). HIV-infected hosts had higher rates of TB progression and mortality [66], much higher risk of fast progression to disease after *M. Tb* infection, a reduced ability to resist reinfection, a lower probability of self-cure in the absence of treatment and higher risk of TB-induced death if untreated [67–70]. HIV-infected individuals progressing to active TB disease were more likely to have extrapulmonary or smear-negative forms of disease, making them, on average, less infectious per unit of time than HIV-seronegative hosts with active TB. HIV transmission could occur as a result of contact between an individual with HIV infection and a vulnerable individual not yet infected with HIV; following [71], we assumed that only a fraction of the population had behavioral risk factors that put them at risk of HIV infection.

Heterogeneity among *M. Tuberculosis*: incorporating drug resistance

We categorized the circulating strains of mycobacteria by the number of antibiotics to which they were resistant and their reproductive fitness (Figure 2b). We assumed that the acquisition of resistance to any class of anti-TB drugs reduced treatment efficiency but also imposed a reproductive fitness cost on the mycobacteria [72–75]. These fitness costs could be partially restored over time as a result of accumulation of compensatory mutations [59,76–78]. We made the assumption that fitness costs of resistance-conferring mutations and the frequency and restoration effect of compensatory mutation were comparable for each class of anti-tuberculosis drug, a simplification that allowed us to dramatically reduce the number of model compartments. This assumption permitted us to classify broad categories of resistance ($n = 0$ for DS strain; 1 for single DR; 2 for MDR; 3 for XDR) and to tally compensatory events ($0 \leq k \leq n$) without specifying the pattern of resistance/compensations. Accordingly, the set of two numbers (n, k) fully described the resistance level and compensatory state of each mycobacterial strain in the model. The mycobacterial state (n, k) could change as a result of two events: 1) inadequate treatment could result in selection of mycobacteria with additional resistance which led to an increase in n and a subsequent reduction in fitness in the absence of drug treatment; or 2) sporadic mutation could occur that compensated for a fraction of the fitness cost associated with resistance which led to an increase in k .

Interaction of bacteria with heterogeneous fitness with heterogeneous hosts: incorporating immune response and immunosuppression

For each mycobacterial state (n, k), we assumed a fitness that decreases monotonically with every additional drug resistance mutation (n) and was partially restored by every compensatory mutation (k), as shown on the Y-axis in Figure 2b. We assumed that a reduction in fitness led to decreased ability for the strain to cause both rapid progression to TB disease and reactivation from latency.

We represented the strength of the immune response of the host by specifying a fitness threshold that the bacteria had to exceed to overcome the immune response and cause

disease. Consistent with previous hypotheses and evidence [18,25–26], we implemented a lower (more permissive) “fitness threshold” for HIV-infected hosts than for hosts with intact immunity (see Figure 2b for a graphical depiction of these thresholds and Figure S1 in Supplement for additional details).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: The work is supported by NIH grants DP2OD006663 and U54GM088558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Office of the Director, the National Institute Of General Medical Sciences or the National Institutes of Health. Author contributions: Study conception (RS,TC), model development (RS,TC), model implementation (RS), writing (RS,CC,MM,TC).

References and Notes

1. Global tuberculosis control 2011. Geneva, Switzerland: WHO report, World Health Organization; 2011.
2. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. *Current Opinion in HIV and AIDS*. 2009; 4:325–333. [PubMed: 19532072]
3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV Infection-Associated Tuberculosis: The Epidemiology and the Response. *Clinical Infectious Diseases*. 2010; 50:S201–S207. [PubMed: 20397949]
4. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV Infection and Multidrug-Resistant Tuberculosis – The Perfect Storm. *The Journal of Infectious Diseases*. 2007; 196:S86–S107. [PubMed: 17624830]
5. Multidrug and extensively drug-resistant TB (M/XDR-TB). Geneva, Switzerland: WHO global report on surveillance and response, World Health Organization; 2010. [Figure 4 from page 14 of the report is adopted as Figure 1a with permission from WHO]
6. Chaisson RC, Slutkin G. Tuberculosis and Human Immunodeficiency Virus Infection. *The Journal of Infectious Diseases*. 1989; 159:96–100. [PubMed: 2642524]
7. Harries AD, Dye C. Tuberculosis. *Annals of Tropical Medicine & Parasitology*. 2006; 100:415–431. [PubMed: 16899146]
8. Lawn SD, Bekker L-G, Middelkoop K, Myer L, Wood R. Impact of HIV Infection on the Epidemiology of Tuberculosis in a Peri-Urban Community in South Africa: The Need for Age-Specific Interventions. *Clinical Infectious Diseases*. 2006; 42:1040–1047. [PubMed: 16511773]
9. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. *AIDS*. 2008; 22:1859–1867. [PubMed: 18753936]
10. Shah NS, Wright A, Bai G-H, Barrera L, Boulahbal F, Martin-Casabona N, Drobniewski F, Gilpin C, Havelkova M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rusch-Gerdes S, van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerging Infectious Diseases*. 2007; 13:380–387. [PubMed: 17552090]
11. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet*. 2006; 368:1575–1580. [PubMed: 17084757]
12. Ravigliione MC. Facing extensively drug-resistant tuberculosis - A hope and a challenge. *New England Journal of Medicine*. 2007; 356:656–659. [PubMed: 17301295]
13. Lazarus JV, Olsen M, Ditiu L, Matic S. Tuberculosis–HIV co-infection: policy and epidemiology in 25 countries in the WHO European region. *HIV Medicine*. 2008; 9:406–414. [PubMed: 18410353]

14. Murray, M.; Cohen, T. Extensively Drug-Resistant Tuberculosis and HIV/AIDS. In: Kaufmann, SHE.; Walker, BD., editors. *AIDS and Tuberculosis: A Deadly Liaison*. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co KGaA; 2009.
15. Espinal MA, Perez EN, Baez J, Henriquez L, Fernandez K, Lopez M, Olivo P, Reingold AL. Infectiousness of *Mycobacterium tuberculosis* in HIV-1-infected patients with tuberculosis: a prospective study. *Lancet*. 2000; 355:275–280. [PubMed: 10675075]
16. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker L-G. Undiagnosed Tuberculosis in a Community with High HIV Prevalence – Implications for Tuberculosis Control. *American Journal of Respiratory and Critical Care Medicine*. 2007; 175:87–93. [PubMed: 16973982]
17. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, Hayes R, Churchyard G, Butterworth A, Mason P. Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. *PLoS Medicine*. 2007; 4:164–172.
18. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. *Science*. 2002; 295:2042–2046. [PubMed: 11896268]
19. Suchindran S, Brouwer ES, van Rie A. Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review. *PLoS ONE*. 2009; e5561 [and references therein].
20. Sanchez-Padilla E, Dlamini T, Ascorra A, Rusch-Gerdes S, Tefera ZD, Calain P, de la Tour R, Jochims F, Richter E, Bonnet M. High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010. *Emerging Infectious Diseases*. 2012; 18:29–37. [PubMed: 22260950]
21. Blower SM, Dowlatabadi H. Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: An HIV Model, as an Example. *International Statistical Review*. 1994; 62:229–243.
22. Tuberculosis country profiles. Geneva, Switzerland: WHO's global TB database, World Health Organization; 2011. available at <http://www.who.int/tb/country/data/profiles/en/index.html>
23. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The Growing Burden of Tuberculosis – Global Trends and Interactions with the HIV Epidemic. *Archives of Internal Medicine*. 2003; 163:1009–1021. [PubMed: 12742798]
24. Cohen T, Murray M. Modeling epidemics of multidrug-resistant *M-tuberculosis* of heterogeneous fitness. *Nature Medicine*. 2004; 10:1117–1121.
25. Strauss OJ, Warren RM, Jordaan A, Streicher EM, Hanekom M, Falmer AA, Albert H, Trollip A, Hoosain E, van Helden PD, Victor TC. Spread of a Low-Fitness Drug-Resistant *Mycobacterium tuberculosis* Strain in a Setting of High Human Immunodeficiency Virus Prevalence. *Journal of Clinical Microbiology*. 2008; 46:1514–1516. [PubMed: 18272712]
26. Bifani P, Mathema B, Kurepina N, Shashkina E, Bertout J, Blanchis AS, Moghazeh S, Driscoll J, Gicquel B, Frothingham R, Kreiswirth BN. The Evolution of Drug Resistance in *Mycobacterium tuberculosis*: from a Mono-Rifampin-Resistant Cluster into Increasingly Multidrug-Resistant Variants in an HIV-Seropositive Population. *The Journal of Infectious Diseases*. 2008; 198:90–94. [PubMed: 18498237]
27. Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, Dye C. HIV Infection, Antiretroviral Therapy, and CD4+ Cell Count Distributions in African Populations. *Journal of Infectious Diseases*. 2006; 194:1450–1458. [PubMed: 17054076]
28. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, de Cock KM, Wood R. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? *The International Journal of Tuberculosis and Lung Disease*. 2011; 15:571–581. [PubMed: 21756508]
29. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, de Cock KM, Hayes RJ, Williams BG, Churchyard GJ. Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners. *American Journal of Respiratory and Critical Care Medicine*. 2004; 170:673–679. [PubMed: 15191919]
30. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. *Nature Medicine*. 2004; 10:1111–1116.
31. Colijn C, Cohen T, Murray M. Latent Coinfection and the Maintenance of Strain Diversity. *Bulletin of Mathematical Biology*. 2009; 71:247–263. [PubMed: 19082663]

32. Sergeev R, Colijn C, Cohen T. Models to understand the population-level impact of mixed strain *M. tuberculosis* infections. *Journal of Theoretical Biology*. 2011; 280:88–100. [PubMed: 21514304]
33. Boni MF, Feldman MW. Evolution of antibiotic resistance by human and bacterial niche construction. *International Journal of Organic Evolution*. 2005; 59:477–491.
34. Atun RA, Lebcir R, Drobniewski F, Coker RJ. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model. *International Journal of STD & AIDS*. 2005; 16:560–570. [PubMed: 16105192]
35. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, Moodley P, Galvani AP, Friedland GH. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. *Lancet*. 2007; 370:1500–1507. [PubMed: 17964351]
36. Sharomi O, Podder CN, Gumel AB. Mathematical Analysis of the Transmission Dynamics of HIV/TB Coinfection in the Presence of Treatment. *Mathematical Biosciences and Engineering*. 2008; 5:145–174. [PubMed: 18193936]
37. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. *Proceedings of the National Academy of Sciences*. 2008; 105:11293–11298.
38. Basu S, Galvani AP. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. *Epidemiology and Infection*. 2008; 136:1585–1598. [PubMed: 18606028]
39. Dye C, Espinal MA. Will Tuberculosis Become Resistant to All Antibiotics? *Biological Sciences*. 2001; 268:45–52. [PubMed: 12123297]
40. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness cost of drug resistance in *Mycobacterium tuberculosis*. *Proceedings of the National Academy of Sciences*. 2009; 106:14711–14715.
41. zur Wiesch PS, Engelstadter J, Bonhoeffer S. Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations. *Antimicrobial Agents and Chemotherapy*. 2010; 54:2085–2095. [PubMed: 20176903]
42. Borell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in *Mycobacterium tuberculosis*. *Clinical Microbiology and Infection*. 2011; 17:815–820. [PubMed: 21682802]
43. Wallace B. Can "Stepping Stones" Form Stairways? *The American Naturalist*. 1989; 133:578–579.
44. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. *New England Journal of Medicine*. 1992; 326:1514–1521. [PubMed: 1304721]
45. Guerrero A, Cobo J, Fortun J, Navas E, Quereda C, Asensio A, Canon J, Blazquez J, Gomez-Mampaso E. Nosocomial transmission of *Mycobacterium bovis* resistant to 11 drugs in people with advanced HIV-1 infection. *Lancet*. 1997; 350:1738–1742. [PubMed: 9413465]
46. Braun MM, Kilburn JO, Smithwick RW, Coulibaly IM, Coulibaly D, Silcox VA, Gnaore E, Adjorlolo G, de Cock KM. HIV infection and primary resistance to antituberculosis drugs in Abidjan Cote d'Ivoire. *AIDS*. 1992; 6:1327–1330. [PubMed: 1335274]
47. Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993. *AIDS*. 1996; 10:299–309. [PubMed: 8882670]
48. Anastasis D, Pillai G, Rambiritch V, Abdool Karim SS. A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa. *The International Journal of Tuberculosis and Lung Disease*. 1997; 1:220–224. [PubMed: 9432367]
49. Post FA, Wood R. HIV infection is not associated with an increased rate of drug-resistant tuberculosis. *South African Medical Journal*. 1997; 87:903. [PubMed: 9259732]
50. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. *South African Medical Journal*. 2000; 90:381–386. [PubMed: 10957924]

51. Mac-Arthur A, Gloyd S, Perdigao P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. *The International Journal of Tuberculosis and Lung Disease*. 2001; 5:894–902. [PubMed: 11605881]
52. Weyer K, Brand J, Lancaster J, Levin J, van der Walt M. Determinants of multidrug-resistant tuberculosis in South Africa: results from a national survey. *South African Medical Journal*. 2007; 97:1120–1128.
53. Anti-tuberculosis drug resistance in the world. World Health Organization, Geneva, Switzerland: WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance; 2008.
54. Morozova I, Riekstina V, Sture G, Wells C, Leimane V. Impact of the growing HIV-I epidemic on multidrug-resistant tuberculosis control in Latvia. *The International Journal of Tuberculosis and Lung Disease*. 2003; 7:903–906. [PubMed: 12971677]
55. Dubrovina I, Miskinis K, Lyepshina S, Yann Y, Hoffmann H, Zaleskis R, Nunn P, Zignol M. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? *The International Journal of Tuberculosis and Lung Disease*. 2008; 12:756–762. [PubMed: 18544200]
56. Louw GE, Warren RM, van Pittius NCG, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CRE, Grobbelaar M, Murray M, van Helden PD, Victor TC. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant *Mycobacterium tuberculosis* through Efflux. *American Journal of Respiratory and Critical Care Medicine*. 2011; 184:269–276. [PubMed: 21512166]
57. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. *Cell*. 2011; 145:39–53. [PubMed: 21376383]
58. Dye C, Williams BG. Slow Elimination of Multidrug-Resistant Tuberculosis. *Science Translational Medicine*. 2009; 1:3ra8.
59. Gagneux S. Fitness cost of drug resistance in *Mycobacterium tuberculosis*. *Clinical Microbiology and Infection*. 2009; 15:66–68. [PubMed: 19220360]
60. Tounghousova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Impact of drug resistance on fitness of *Mycobacterium tuberculosis* strains of the W-Beijing genotype. *Immunology and Medical Microbiology*. 2004; 42:281–290. [PubMed: 15477041]
61. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the *Mycobacterium tuberculosis* Beijing genotype strains. *Lancet Infectious Diseases*. 2010; 10:103–111. [PubMed: 20113979]
62. Vynnycky E, Fine PEM. The Natural History of Tuberculosis: The Implications of Age-Dependent Risks of Disease and the Role of Reinfection. *Epidemiology and Infection*. 1997; 119:183–201. [PubMed: 9363017]
63. Sutherland I, Svandova E, Radhakrishna S. The Development of Clinical Tuberculosis Following Infection with Tubercle-Bacilli. *Tubercle*. 1982; 63:255–268. [PubMed: 6763793]
64. Brooks-Pollock E, Becerra MC, Goldstein E, Cohen T, Murray M. Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru. *Journal of Infectious Diseases*. 2011; 203:1582–1589. [PubMed: 21592987]
65. Myers JA. Natural History of Tuberculosis in Human Body – 45 Years of Observation. *Journal of the American Medical Association*. 1965; 194:1086–1092. [PubMed: 5294688]
66. Currie CS, Williams BG, Cheng RC, Dye C. Tuberculosis epidemics driven by HIV: Is prevention better than cure? *AIDS*. 2003; 17:2501–2508. [PubMed: 14600522]
67. Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, Huaroto L, Ticona E, Ortiz J, Tovar M, Chavez V, Rodriguez R, Escombe AR, Evans CA. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. *The American Journal of Tropical Medicine and Hygiene*. 2006; 75:1027–1033. [PubMed: 17172361]
68. Cain KP, Kanara N, Laserson KF, Vannarith C, Sameoun K, Samnang K, Qualls ML, Wells CD, Varma JK. The epidemiology of HIV-associated tuberculosis in rural Cambodia. *The International Journal of Tuberculosis and Lung Disease*. 2007; 11:1008–1013. [PubMed: 17705980]
69. Moore D, Liechty C, Ekwarua P, Were W, Mwima G, Solberg P, Rutherford G, Mermin J. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. *AIDS*. 2007; 21:713–719. [PubMed: 17413692]

70. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. *AIDS*. 2008; 22:2527–2533. [PubMed: 19005276]
71. Estimation and Projection Package 2009. UNAIDS manual for generalized epidemics, Joint United Nations Programme on HIV/AIDS; 2009. available at <http://www.unaids.org/en/dataanalysis/tools/epp2009/>
72. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of *Mycobacterium tuberculosis*. *Lancet Infectious Diseases*. 2003; 3:13–21. [PubMed: 12505028]
73. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? *Current Opinion in Microbiology*. 2006; 9:461–465. [PubMed: 16890008]
74. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannon BJM. The Competitive Cost of Antibiotic Resistance in *Mycobacterium tuberculosis*. *Science*. 2006; 312:1944–1946. [PubMed: 16809538]
75. Kang Y-S, Park W. Trade-off between antibiotic resistance and biological fitness in *Acinetobacter* sp. Strain DR1emi. *Environmental Microbiology*. 2010; 12:1304–1318. [PubMed: 20192959]
76. Reynolds MG. Compensatory Evolution in Rifampin-Resistant *Escherichia coli*. *Genetics*. 2000; 156:1471–1481. [PubMed: 11102350]
77. Gillespie SH, Billington OJ, Breathnach A, McHugh TD. Multiple Drug-resistant *Mycobacterium tuberculosis*: Evidence for Changing Fitness Following Passage Through Human Hosts. *Microbial Drug Resistance*. 2002; 8:273–279. [PubMed: 12523624]
78. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant *Mycobacterium tuberculosis*. *The International Journal of Tuberculosis and Lung Disease*. 2009; 13:1456–1466. [PubMed: 19919762]
79. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. *Annals of Internal Medicine*. 2008; 149:123–134. [PubMed: 18626051]
80. Mathematica 8.0.1.0 for Mac OSX x86. Wolfram Research Inc;
81. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, Taelman H, Vandepierre P, Serufilira A, Bogaerts J, Slutkin G, Hopewell PC. Two-year incidence of tuberculosis in cohorts of HIV infected and uninfected urban Rwandan women. *American Review of Respiratory Diseases*. 1992; 146:1439–1444. [PubMed: 1456559]
82. Mulder D, Nunn A, Kamali A, Nakiyingi J, Wagner HU, Kengeyakayondo JF. Two-year HIV-1 associated mortality in a Ugandan rural population. *Lancet*. 1994; 343:1021–1023. [PubMed: 7909054]
83. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. *The Journal of the American Medical Association*. 1996; 276:1223–1228.
84. Hilleboe HE. Post-sanatorium tuberculosis survival rates in Minnesota. *Public Health Reports*. 1941; 56:895–907.
85. Berg G. The prognosis of open pulmonary tuberculosis. A clinical statistical analysis. *Acta Tuberculosea Scandinavica suppl*. 1939; 4:1–207.
86. Drolet G. Present trend of case fatality rates in tuberculosis. *American Review of Tuberculosis*. 1938; 37:125–151.
87. Springett V. Ten-year results during the introduction of chemotherapy for tuberculosis. *Tubercle*. 1971; 52:73–87. [PubMed: 5560737]
88. Lowe CR. Recent trends in survival of patients with respiratory tuberculosis. *British Journal of Preventive and Social Medicine*. 1954; 8:91–98. [PubMed: 13190162]
89. National Tuberculosis Institute, Bangalore, Tuberculosis in a rural population in South India: a five year study. *Bulletin of the World Health Organization*. 1974; 51:473. [PubMed: 4549498]
90. Thompson B. Survival rates in pulmonary tuberculosis. *British Medical Journal*. 1943; 2:721. [PubMed: 20785165]
91. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of Tuberculosis In Patients with Advanced Human-Immunodeficiency-Virus Infection. *New England Journal of Medicine*. 1991; 324:289. [PubMed: 1898769]

92. Palmieri F, Pellicelli AM, Girardi E, de Felici AP, de Mori P, Petrosillo N, Ippolito G. Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. *Infection*. 1999; 27:331–334. [PubMed: 10624592]
93. Nunn P, Brindle R, Carpenter L. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6 month) mortality. *American Review of Respiratory Diseases*. 1992; 146:849–854. [PubMed: 1416409]
94. Perriens JH, st Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. *New England Journal of Medicine*. 1995; 332:779–784. [PubMed: 7862181]
95. Rutledge JA, Crouch JB. The ultimate results in 1694 cases of tuberculosis treated at the Modern Woodmen Sanitorium of America. *American Review of Tuberculosis*. 1919; 2:755–756.
96. Tattersall WH. The survival of sputum positive consumptives. A study of 1192 cases in a county borough between 1914 and 1940. *Tubercle*. 1947; 28:85–96. [PubMed: 20240306]
97. Madsen T, Holm J, Jensen KA. Studies on the epidemiology of tuberculosis in Denmark. *Acta Tuberculosea Scandinavica suppl*. 1942; 6:1–176.
98. Bergqvist S, Ernberg T. Zur Frage der tuberkulösen Primärinfektion bei jungen Erwachsenen. *Acta Medica Scandinavica*. 1943; 115:57–82.
99. Daley C, Small P, Schechter G, Schoolnik GK, Mcadam RA, Jacobs WR, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. *New England Journal of Medicine*. 1992; 326:231–235. [PubMed: 1345800]
100. di Perri G, Danzi M, Dehecchi G, Pizzighella S, Solbiati M, Bassetti D, Cruciani M, Luzzati R, Malena M, Mazzi R, Concia E. Nosocomial epidemic of active tuberculosis among HIV - infected patients. *Lancet*. 1989; 2:1502–1504. [PubMed: 2574778]
101. Nunn P, Mungai M, Nyamwaya J, Gicheha C, Brindle RJ, Dunn DT, Githui W, Were JO, Mcadam KPWJ. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. *Tubercle and Lung Disease*. 1994; 75:25–32. [PubMed: 8161761]
102. Barnett G, Grzybowski S, Styblo KM. Present risk of developing active tuberculosis in Saskatchewan according to previous tuberculin and X-ray status. *Bulletin of the International Union Against Tuberculosis*. 1971; 45:51–74.
103. Comstock GW, Livesay VT, Woolpert SF. The Prognosis of a Positive Tuberculin Reaction in Childhood and Adolescence. *American Journal of Epidemiology*. 1974; 99:131–138. [PubMed: 4810628]
104. Styblo K. *Epidemiology of Tuberculosis*. The Hague, Royal Netherlands Tuberculosis Association KNCV. 1991
105. Holmes CB, Wood R, Badri M, Zilber S, Wang BX, Maartens G, Zheng H, Lu ZG, Freedberg KA, Losina E. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment. *Journal of Acquired Immune Deficiency Syndromes*. 2006; 42:464–469. [PubMed: 16810113]
106. Gilks CF, Godfrey-Faussett P, Batchelor BIF, Ojoo JC, Ojoo SJ, Brindle RJ, Paul J, Kimari J, Bruce MC, Bwayo J, Plummer FA, Warrell DA. Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. *AIDS*. 1997; 11:911–918. [PubMed: 9189217]
107. Glynn JR. Resurgence of tuberculosis and the impact of HIV infection. *British Medical Bulletin*. 1998; 54:579–593. [PubMed: 10326286]
108. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A Prospective-Study of the Risk of Tuberculosis Among Intravenous Drug-Users with Human Immunodeficiency Virus-Infection. *New England Journal of Medicine*. 1989; 320:545–550. [PubMed: 2915665]
109. Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. *Journal of the Royal Society Interface*. 2008; 5:653–662.

110. Cauthen GM, Dooley SW, Onorato IM, Ihle WW, Burr JM, Bigler WJ, Witte J, Castro KG. Transmission of Mycobacterium Tuberculosis from Tuberculosis Patients with HIV infection of AIDS. *American Journal of Epidemiology*. 1996; 44:69–77. [PubMed: 8659487]
111. Colebunders R, Ryder R, Nzilambi N, Dikilu K, Willame JC, Kaboto M, Bagala N, Jeugmans J, Muepu K, Francis HL, Mann JM, Quinn TC, Piot P. HIV infection in patients with tuberculosis in Kinshasa, Zaire. *American Review of Respiratory Disease*. 1989; 139:1082–1085. [PubMed: 2496632]
112. de Cock KM, Gnaore E, Adjorlolo G, Braun MM, Lafontaine MF, Yesso G, Bretton G, Coulibaly IM, Gershydamet GM, Bretton R, Heyward WL. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. *British Medical Journal*. 1991; 301:496–499. [PubMed: 1849431]
113. Elliott A, Hayes R, Halwiindi B, Luo N, Tembo G, Pobee JOM, Nunn PP, Mcadam KPWJ. The impact of HIV infectiousness of pulmonary tuberculosis: a community study in Zambia. *AIDS*. 1993; 7:981–987. [PubMed: 8357557]
114. Githui W, Nunn P, Juma E, Karimi F, Brindle R, Kamunyi R, Gathua S, Gicheha C, Morris J, Omwega M. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. *Tubercle and Lung Disease*. 1992; 73:203. [PubMed: 1477386]
115. Sonnenberg P, Murray J, Shearer S, Glynn JR, Kambashi B, Godfrey-Faussett P. Tuberculosis treatment failure and drug resistance-same strain or reinfection? *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2000; 94:603–607. [PubMed: 11198641]

Figure 1. Reported individual-level associations between HIV and MDRTB

a) Forest plot depicting the association between cases of HIV infection and MDRTB and corresponding 95% confidence intervals in countries reporting at least one MDRTB case among patients with HIV-positive and HIV-negative status in population-representative TB drug resistance surveys/surveillance. The plot is adopted from WHO 2010 report [5] with permission from WHO.

b) Figure adapted from Suchindran *et al.* 2011 [19]. Forest plot of MDRTB prevalence ratios by HIV status and corresponding 95% confidence intervals from studies in Sub-

Saharan Africa regions (see references therein for studies included). The result of the latest study Sanchez-Padilla *et al.* 2012 [20] is added.

Figure 2. Simplified model structure

a) Schematic overview of the mathematical model of TB/HIV dynamics. The natural history of tuberculosis is represented by compartments for Susceptibles (S), Latently infected (L), and Infectious individuals (I). HIV-seropositive individuals are designated by the + superscript. Details of flow between compartments and model equations are provided in the Supplementary Materials.

b) Fitness mapping of mycobacterial strains modeled by number of drug resistances ($n=0$ for DS strain; 1 for single DR; 2 for MDR; 3 for XDR; etc) and by the number of compensatory events ($0 \leq k \leq n$, one compensatory mutation per each resistance). The pair of numbers (n, k)

defines each type of mycobacteria modeled. The Y-axis shows the relative fitness of each strains compared to wild type on the log-scale (according to equation 4). Assumed fitness thresholds for HIV– and HIV+ individuals are shown by the thin dashed black lines for a reference.

Figure 3. Simulated epidemics

a) The total TB incidence and HIV prevalence (black solid and grey dashed lines) in comparison with the data for adults (age 15+) from Swaziland [22] (black dots and gray squares with corresponding 95% confidence intervals respectively). The inset shows the data and approximations used for case-finding (gray) and treatment success (black).

b) Modeled trends of the incidence of drug sensitive, drug resistant, and multi-drug resistant (MDR) in populations with epidemic HIV (solid lines) and without HIV (thick dashed lines).

Figure 4. Trends in the individual-level association between HIV and DRTB

The projected trends in the percentage of TB incidence (left panels) that is with: **a)** DR strains; and **b)** MDR strains. For panels **a–b**, trends for HIV+ and HIV– individuals within populations with epidemic HIV are represented by dashed lines and solid lines, respectively. The trend for individuals in populations unaffected by HIV is shown with a thin dashed line. The right panels show the prevalence ratios of drug-resistance between HIV-seropositive and HIV-seronegative hosts (*PR*) in the population with epidemic HIV. A value *PR*=1, representing the absence of association between drug resistance of *M. Tb* and HIV, is shown as thin gray line.

c) The fraction of total MDRTB that is due to transmission (left panel). The right panel shows the prevalence ratio (*PR*) for transmitted (solid line) and acquired (dashed line) MDRTB.

Figure 5. Trends in the average relative fitness of DRTB and its impact on prevalence ratio
a) Relative fitness values are compared with the referent drug sensitive TB. The solid lines represent the fitness trends in populations with both TB and HIV. The dashed lines show the fitness trajectories in an HIV-free population. The *maximum* possible values for the fitness of each type of resistance (i.e. where all resistance mutations are accompanied by compensatory mutations, $k=n$) are: 0.99 for DR TB; 0.98 for MDR TB; and 0.97 for XDR TB. Trends in fitness for the resistant strains do not approach these maximal levels over the next several decades in our simulations.

b) Prevalence ratio (*PR*) of drug-resistance between HIV-seropositive and HIV-seronegative hosts for low-fit ($k=0$, solid lines) and high-fit ($k=n$, dashed lines) drug-resistant strains. Strains with different number of resistances are represented by shading: DR ($n=1$) – light gray; MDR ($n=2$) – gray; and XDR ($n=3$) – black.

Figure 6. Multivariable sensitivity analysis

Distribution of 3000 simulation runs with model parameter sets sampled over the ranges listed in Table S1. The mean value is shown by the dotted line; the bars indicate one standard deviation above and below this mean value. The three panels show: **a)** the individual-level association (*PR*) between MDRTB and HIV; **b)** The prevalence of HIV (%); **c)** The incidence of all forms of TB (per 100 000).

Figure 7. Effects of altering of key model parameters

The left panels indicate the trend in the proportion of TB that is MDR and right panels indicate the trend in the individual-level relative risk of MDR among HIV-seropositive and HIV-seronegative hosts with TB. The solid lines represent an increase in the value of each parameter over baseline, dashed lines represent a decrease in the value, and the thin dashed lines represent a baseline value. Shown on the panels are:

- Variation of the fitness threshold for HIV-seropositives compared to hosts without HIV. Solid line: fitness thresholds are equal; thin dashed line: fitness threshold for HIV-seropositives is 0.75 of that for HIV-seronegatives.
- Variation of mixing patterns. Solid line: assortative mixing such that individuals with the same HIV status are twice as likely to contact each other; thin dashed line: homogeneous mixing (see Supplement for additional details).
- Variation of the relative rate of case detection. The probability of case detection before self-cure or death is set to be 50% higher (solid), equal (thin dashed), and 50% lower (dashed) for a HIV-coinfected TB patient than a TB patient without HIV.